Mental disorders and metabolic syndrome;Psihičke bolesti i metabolički sindrom

Socijalna Psihijatrija

Volumn 35, Issue 1, 2007, Pages 13-20

  Martinac, Marko ^a,e,f   Karlović, Dalibor ^a,f   Marčinko, Darko ^b,c,g   Babić, Dragan ^d,h   Maslov, Boris ^d,h   Jakovljević, Miro ^b,c,g  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b KBC Zagreb   (Croatia)

^c Odjel za Psihijatriju ^*

^d Klini ka Bolnica Mostar   (Bosnia and Herzegovina)

^e Klin Bolnica Sestre Milosrdnice   (Croatia)

^f University Department of Neurology   (Croatia)

^g UNIVERSITY OF ZAGREB   (Croatia)

^h UNIVERSITY OF MOSTAR   (Bosnia and Herzegovina)

Author keywords

Depression; HPA; Metabolic syndrome; Schizophrenia; Stress

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; GLUCOSE; HYDROCORTISONE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ABDOMINAL OBESITY; AMNESIA; ARTICLE; BLINDNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CUSHING SYNDROME; DEPRESSION; DIABETES MELLITUS; DRUG SAFETY; DYSLIPIDEMIA; EATING HABIT; EPIDEMIOLOGICAL DATA; FRACTURE; GLUCOSE METABOLISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMOBILIZATION; INSULIN RESISTANCE; MENTAL DISEASE; MENTAL PATIENT; METABOLIC DISORDER; METABOLIC SYNDROME X; MOOD DISORDER; MORTALITY; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PUBLIC HEALTH; RISK FACTOR; STROKE;

EID: 34247270815     PISSN: 03037908     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Lakka HM, Laaksonen DE, Lakka TA i sur. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged man. JAMA 2002;28:2709-16.
2. Mokdad AH, Ford ES, Bowman BA i sur. Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 2003;289:76-9.
3. Takeshita J, Masaki K, Ahmed I i sur. Are depressive symptoms a risk factor for mortality in elderly Japanese American men? The Honolulu-Asian Aging Study. Am J Psychiatry 2002;159:1127-32.
4. Perlmutter JB, Frishman WH, Feinstein RE. Major depression as a risk factor for cardiovascular disease: Therapeutic implications. Heart Dis 2000;2:75-82.
5. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: A meta-analysis. Diabetes Care 2000;24:1069-78.
6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
7. Expert Panel (ATP III). Executive Summary of The Third Report of The National Cholesterol Education Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
8. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2000;102:42-7.
9. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002;53:865-71.
10. Bjorntorp P, Rosmond R. Hypothalamic origin of the metabolic syndrome X. Ann NY Acad Sci 1999;892:297-307.
11. Bruner EJ, Hemingway H, Walker BR i sur. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002;106:2659-65.
12. Bjorntorp P. Visceral obesity: a "Civilization Syndrome." Obesity Res 1993;1:206-22.
13. Shively C, Clarkson TB, Miller CL, Weingard JW. Body fat distribution as a risk factor for coronary artery atherosclerosis in female Cynomolgus monkeys. Arteriosclerosis 1987;7:226-31.
14. Montague C, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000;49:883-8.
15. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
16. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993;44:121-31.
17. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000;106:453-8.
18. Steinberg H, Chaker H, Learning R i sur. Obesity/insulin resistance is asociated with endothelial disfunction: implication for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-10.
19. Reaven GM. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002;106:286-8.
20. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473-81.
21. Ginsberg HN, Stalenhoef AF. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. J Cardiovasc Risk 2003;10:121-8.
22. Hotta K, Funahashi T, Arita Y i sur. Plasma concentrations of novel, adipose specific protein, adiponectin, in type 2 diabetic patient. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
23. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002;105:2696-8.
24. Mertens I, Van der PM, Corthouts B i sur. Visceral fat is determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 2001;33:602-7.
25. Björntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990;10:493-6.
26. Reul JMHM, de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 1985;117:2505-12.
27. Funder JW. Corticosteroid receptors and the central nervous system. J Steroid Biochem Mol Biol 1994;49:381-4.
28. Mauri M, Sinforiani E, Bono G i sur. Memory impairment in Cushing's disease. Acta Neurol Scand 1997;87:52-5.
29. Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume, memory dysfunction, and Cortisol levels in patients with Cushing's syndrome. Biol Psychiatry 1992;32:756-65.
30. Tauchmanova L, Rossi R, Biondi B i sur. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002;87:4872-8.
31. Young EA, Haskett RF, Murphy-Weinberg V, Watson SJ, Akil H. Loss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry 1991;48:693-9.
32. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991;43:425-73.
33. Yehuda R, Boisoneau D, Mason JW, Giller EL. Glucocorticoid receptor number and cortisol excretion in mood, anxiety, and psychotic disorders. Biol Psychiatry 1993;34:18-25.
34. Van Cauter E, Spiegel K. Sleep as a mediator of the relationship between socioeconomic status and health: A hypothesis. Ann N Y Acad Sci 1999;896:254-61.
35. Brown ES, Rush AJ, McEwen BS. Hippocampal remodeling and damage by corticosteroids: Implications for mood disorders. Neuropsychopharmacology 1999;21:474-84.
36. Cizza G, Ravn P, Chrousos GP, Gold PW. Depression: A major, unrecognized risk factor for osteoporosis? Trends Endocrinol Metab 2001;12:198-203.
37. Rubinow DR, Post RM, Savard R, Gold PW. Cortisol hypersecretion and cognitive impairment in depression. Arch Gen Psychiatry 1984;41:279-83.
38. Weber-Hamann B, Hentschel F, Kniest A i sur. Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 2002;64:274-7.
39. Schweiger U, Weber B, Deuschle M, Heuser I. Lumbar bone mineral density in patients with major depression: Evidence of increased bone loss at follow-up. Am J Psychiatry 2000;157:118-20.
40. Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE. Depression and risk for onset of type II diabetes-a prospective population-based study. Diabetes Care 1996;19:1097-1502.
41. Davidson K, Jonas BS, Dixon KE, Markovitz JH. Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study? Coronary artery risk development in young adults. Arch Intern Med 2000;160:1495-1500.
42. Karlović D, Buljan D, Martinac M, Marčinko D. Serum lipid concentrations in Croatian veterans with post-traumatic stress disorder, post-traumatic stress disorder comorbid with major depressive disorder, or major depressive disorder. J Korean Med Sci 2004;19:431-6.
43. Räikkönen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism 2002;51:1573-7.
44. Roberts RE, Deleger S, Strawbridge WJ i sur. Prospective association between obesity and depression: evidence from the Alameda County Study. Int J Obes Relat Metab Disord 2003;27:514-21.
45. Adamis D, Ball C. Physical morbidity in elderly psychiatric inpatients: Prevalence and possible relations between the major mental disorders and physical illness. Int J Geriatr Psychiatry 2000;15:248-53.
46. Jonas, BS, Franks, P, Ingram, DD. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Fam Med 1997;6:43-9.
47. Eaton WW. Epidemiologic evidence on the comorbidity of depression and diabetes. J Psychosom Res 2002;53:903-6.
48. Kawakami N, Takatsuka N, Shimizu H i sur. Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care 1999;22:1071-6.
49. Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care 1993;16:1167-78.
50. Kovacs M, Obrosky DS, Goldston D, Drash A. Major depressive disorder in youths with IDDM: a controlled prospective study of course and outcome. Diabetes Care 1997;20:45-51.
51. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994;11:105-10.
52. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62:22-31.
53. Thakore JH, Mann JN, Vlahos I i sur. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137-41.
54. Ryan MC, Collins P, Thakore JH. Impaired fast-ing glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-9.
55. Heiskanen T, Niskanen L, Lytikainen R i sur. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-9.
56. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association of the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601.